Gene therapy improves survival and quality of life of dogs with cancer
A new gene therapy has helped pet dogs with cancer live longer and could potentially improve the quality of life and survival of people with cancer, said the therapy's developers. The results of the animal study will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco. The single treatment works by increasing muscle strength and correcting common complications of cancer such as weakness, weight loss and anemia, said principal investigator Ruxandra Draghia-Akli, MD, PhD, researcher, VGX Pharmaceuticals Inc., The Woodlands, Tex.
Such complications occur in more than 50 percent of patients with cancer and, along with loss of appetite and fatigue, result in poor quality of life, she said. If cachexia—muscle wasting and severe weight loss—develops, it can prevent cancer-specific therapy from being given and may be a direct cause of death.
"With our type of gene therapy," Draghia-Akli said, "we can 'trick' certain types of cells in the body to naturally produce specific hormones." These hormones have a muscle-building, or anabolic, effect.
The therapy uses a nonviral DNA molecule, called a plasmid, which encodes for growth hormone-releasing hormone (GHRH). This stimulates the endogenous growth hormone and another growth substance, insulin-like growth factor-1 (IFG-1), which have anabolic effects.
The therapeutic process involves injecting the DNA fragment into a muscle and applying electroporation—short, mild, controlled electric fields—in the area of the injection. It opens the cell membrane pores and traps the DNA inside the cells, which allows the production of GHRH. This thwarts the body's natural process of eliminating a foreign body, in this case the DNA molecule, Draghia-Akli explained.
The researchers tested the gene therapy in 55 companion dogs that had cancer and anemia and were receiving cancer treatment. Three months after the injection, 54 percent of the dogs had responded to gene therapy, as apparent on blood testing. Dogs that responded to therapy survived 84 percent longer, compared with dogs that did not respond to gene therapy and untreated control dogs that received a placebo injection. Although the response rate dropped to 47 percent at 4 months, it was still 22 percent higher than in control dogs.
Also, study data showed quality of life, especially appetite, dramatically improved with the gene therapy, and complications of chemotherapy, such as vomiting and diarrhea were greatly reduced,
Source: The Endocrine Society
Articles on the same topic
- Improving understanding of cell behavior in breast cancerWed, 18 Jun 2008, 15:08:25 UTC
- Team discovers new inhibitors of estrogen-dependent breast cancer cellsMon, 16 Jun 2008, 19:07:52 UTC
- Future hope for patients with breast cancers resistant to tamoxifenMon, 16 Jun 2008, 19:07:46 UTC
- PET scans reveal hormone replacement therapy may be beneficial for postmenopausal womenMon, 16 Jun 2008, 16:07:52 UTC
Other sources
- Team discovers new inhibitors of estrogen-dependent breast cancer cellsfrom Biology News NetMon, 16 Jun 2008, 22:49:23 UTC
- Team discovers new inhibitors of estrogen-dependent breast cancer cellsfrom PhysorgMon, 16 Jun 2008, 19:07:19 UTC
- Anti-estrogen Drug Therapy Reduces Risk Of Invasive Breast Cancer In Older Womenfrom Science DailyMon, 16 Jun 2008, 3:42:36 UTC
- Low Melatonin Associated with Increased Risk of Breast Cancer in Postmenopausal Womenfrom Science DailyMon, 16 Jun 2008, 3:42:33 UTC